High School Reading Grades 11 12 Quiz
14 questions · no time limit
0:00
READING INFORMATIONAL TEXT
Question 1 of 14
No time limit
Current
Answered
Flagged
Not seen
PASSAGE
Source 1: Press release from NovaGen Pharmaceuticals
NovaGen is pleased to announce that its investigational drug, Clarivex, met its primary endpoint in the Phase III MERIDIAN trial, reducing major cardiovascular events by 22 percent compared with placebo (p<0.01) in patients with elevated lipoprotein(a). We anticipate submitting to regulators later this year.
**Source 2: Editorial in the *Journal of Cardiovascular Medicine***
The MERIDIAN results are encouraging but must be interpreted cautiously. The 22 percent figure is a relative risk reduction; the absolute reduction was from 6.4 percent of patients experiencing events to 5.0 percent—a 1.4 percentage-point difference. Furthermore, the trial excluded patients over 75 and those with prior stroke, limiting generalizability. Independent replication and longer follow-up are essential before Clarivex is adopted as standard therapy.
Source 3: Patient advocacy group statement
For the millions of Americans living with elevated lipoprotein(a)—a genetic condition with no approved treatments—MERIDIAN represents historic progress. We urge regulators to expedite approval so that patients are not denied a proven benefit while academics debate statistical nuances.
A reader integrating all three sources would most reasonably conclude that:
YOUR PROGRESS
14
QUESTIONS
Ready when you are
Answer in any order. Your progress shows here as you go.
QUESTIONS
KEYBOARD
Pick an answer ABCD
Next question ↵→
Previous ←
Flag for review F
Answers save as you go · flagged questions come back at the end